Just caught that Dyne reported some pretty hefty losses for Q4 - we're talking $112M net loss, which is actually wider than last year's $89.5M. Per share it came out to $0.76 vs $0.88 year-over-year. Their R&D spend jumped too, hitting $95.4M this quarter compared to $81.8M back in 2024. What's interesting though is Dyne still has $1.1B in cash and equivalents sitting on the balance sheet as of end of December. The company's guidance suggests that cash runway should carry them through to Q1 2028, so at least they've got some runway. Dyne's burning through cash pretty quick with those losses, but biotech companies often operate like this in development phase. Curious how long they can sustain this burn rate before hitting some kind of inflection point. Anyone else watching Dyne's pipeline updates?